Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap
Heart failure (HF) with preserved ejection fraction (EF; HFpEF) accounts for 50% of HF
cases, and its prevalence relative to HF with reduced EF continues to rise. In contrast to HF …
cases, and its prevalence relative to HF with reduced EF continues to rise. In contrast to HF …
A review of the molecular mechanisms underlying the development and progression of cardiac remodeling
L Schirone, M Forte, S Palmerio, D Yee… - Oxidative medicine …, 2017 - Wiley Online Library
Pathological molecular mechanisms involved in myocardial remodeling contribute to alter
the existing structure of the heart, leading to cardiac dysfunction. Among the complex …
the existing structure of the heart, leading to cardiac dysfunction. Among the complex …
Beyond erectile dysfunction: cGMP-specific phosphodiesterase 5 inhibitors for other clinical disorders
Cyclic guanosine monophosphate (cGMP), an important intracellular second messenger,
mediates cellular functional responses in all vital organs. Phosphodiesterase 5 (PDE5) is …
mediates cellular functional responses in all vital organs. Phosphodiesterase 5 (PDE5) is …
Pulmonary hypertension due to left heart diseases
JL Vachiéry, Y Adir, JA Barberà, H Champion… - Journal of the American …, 2013 - jacc.org
Pulmonary hypertension (PH), a common complication of left heart diseases (LHD),
negatively impacts symptoms, exercise capacity, and outcome. Although the true prevalence …
negatively impacts symptoms, exercise capacity, and outcome. Although the true prevalence …
cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action
SH Francis, JL Busch, JD Corbin - Pharmacological reviews, 2010 - ASPET
To date, studies suggest that biological signaling by nitric oxide (NO) is primarily mediated
by cGMP, which is synthesized by NO-activated guanylyl cyclases and broken down by …
by cGMP, which is synthesized by NO-activated guanylyl cyclases and broken down by …
Low myocardial protein kinase G activity in heart failure with preserved ejection fraction
Background—Prominent features of myocardial remodeling in heart failure with preserved
ejection fraction (HFPEF) are high cardiomyocyte resting tension (Fpassive) and …
ejection fraction (HFPEF) are high cardiomyocyte resting tension (Fpassive) and …
In search of new therapeutic targets and strategies for heart failure: recent advances in basic science
AM Shah, DL Mann - The Lancet, 2011 - thelancet.com
Chronic heart failure continues to impose a substantial health-care burden, despite recent
treatment advances. The key pathophysiological process that ultimately leads to chronic …
treatment advances. The key pathophysiological process that ultimately leads to chronic …
PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1 …
Background—In heart failure (HF), a defective nitric oxide signaling is involved in left
ventricular (LV) diastolic abnormalities and remodeling. PDE5 inhibition, by blocking …
ventricular (LV) diastolic abnormalities and remodeling. PDE5 inhibition, by blocking …
Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics
Cyclic guanosine 3', 5'-monophosphate (cGMP) mediates a wide spectrum of physiologic
processes in multiple cell types within the cardiovascular system. Dysfunctional signaling at …
processes in multiple cell types within the cardiovascular system. Dysfunctional signaling at …
Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure
R Kamel, J Leroy, G Vandecasteele… - Nature Reviews …, 2023 - nature.com
Cyclic nucleotide phosphodiesterases (PDEs) modulate the neurohormonal regulation of
cardiac function by degrading cAMP and cGMP. In cardiomyocytes, multiple PDE isozymes …
cardiac function by degrading cAMP and cGMP. In cardiomyocytes, multiple PDE isozymes …